CTTQ
Status and phase
Conditions
Treatments
About
Anlotinib hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor that targets angiogenesis-related kinases such as VEGFR1/2/3, FGFR1/2/3, and other tumor-associated kinases involved in cell proliferation such as PDGFRα/β, c-Kit, and Ret have significant inhibitory activities.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
5.Adequate laboratory indicators. 6.No pregnant or breastfeeding women, and a negative pregnancy test. 7.Understood and signed an informed consent form.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
386 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Yuankai Shi, Doctor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal